se of artificial tears in patients treated with eye (intravitreal) injections
- Conditions
- Eye DiseasesAge-related macular degeneration
- Registration Number
- ISRCTN77853517
- Lead Sponsor
- Oftalmología Vistahermosa S
- Brief Summary
2022 Results article in https://pubmed.ncbi.nlm.nih.gov/36474999/ (added 08/12/2022)
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 34
Current inclusion criteria as of 06/04/2021:
1. Patients with anti-vascular endothelial growth treatment with Lucentis 10mg/ml (ranibizumab, Novartis) for age-related macular degeneration
2. Patients must have already received a minimum of three injections of this treatment
3. Age between 51 and 90 years
_____
Previous inclusion criteria:
1. Patients with anti-vascular endothelial growth treatment with Lucentis 10mg/ml (ranibizumab, Novartis) for age-related macular degeneration
2. Patients must have already received a minimum of three injections of this treatment
3. Age between 50 and 90 years
1. Glaucoma
2. Dry eye
3. Previous refractive surgery or recent cataract surgery (less than 6 months)
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Ocular Surface Discomfort Index questionnaire measured at baseline, 7, 30, 37 and 60 days.
- Secondary Outcome Measures
Name Time Method <br> Measured at baseline, 7, 30, 37 and 60 days:<br> 1. Meniscus tear height measured using Keratograph device<br> 2. Conjunctival hyperemia measured using Keratograph device<br> 3. Non-invasive keratographic tear film break-up time (BUT) measured using Keratograph device<br> 4. Dry eye symptoms measured using the DEQ-5 questionnaire<br> 5. Corneal staining measured using Keratograph device<br> 6. Fluorescein BUT measured using Keratograph device<br> 7. Meibomiography measured using Keratograph devie<br>